Contemporary Pharmacotherapy for OAB 2023: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2023)
Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. The publication of the recently updated AUA/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Guideline titled “Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults,” the proceedings of the 7th International Consultation on Incontinence, as well as European Association of Urology Guidelines have maintained considerable interest in this area among researchers and practitioners. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of OAB, review currently available agents and discuss agents in development.
Independent educational grant support provided by:
- Urovant Sciences, Inc.
At the conclusion of this activity, participants will be able to:
- Define the similarities and differences between the various oral pharmacotherapies for OAB.
- Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy.
- Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
- Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
- Discuss potential future pharmacological pathways and therapies for OAB.
|Name||Company Name||Relationship Type||End Date|
|Eric Scott Rovner, MD||Allergan||Consultant or Advisor||Current|
|Medtronics||Consultant or Advisor||Current|
|Urovant||Scientific Study or Trial||Current|
|Bluewind||Consultant or Advisor||Current|
|Hologix||Consultant or Advisor||Current|
|uromedica||Scientific Study or Trial||04/04/2023|
|Valencia||Consultant or Advisor||Current|
|Avation||Consultant or Advisor||Current|
|Boston Scientific||Meeting Participant or Lecturer||Current|
|Axonics||Consultant or Advisor||Current|
|EG-427||Consultant or Advisor||Current|
|Ironwood||Scientific Study or Trial||Current|
|Synapse IC||Consultant or Advisor||Current|
|Viveve||Consultant or Advisor||04/04/2023|
|Alan J. Wein, MD||Urovant||Consultant or Advisor||Current|
|Christopher R. Chapple, MD||Symimetics||Consultant or Advisor||Current|
|Urovant Sciences||Consultant or Advisor||Current|
|Allergan||Meeting Participant or Lecturer||Current|
|Allergan||Consultant or Advisor||5/18/2021|
|Astellas||Consultant or Advisor||5/14/2021|
|Astellas||Meeting Participant or Lecturer||3/29/2022|
|Bayer Schering Parma AG||Consultant or Advisor||11/12/2021|
|Bayer Schering Parma AG||Scientific Study or Trial||8/23/2021|
|Takeda||Consultant or Advisor||6/23/2021|
|B. Braun||Meeting Participant or Lecturer||Current|
|Proverum||Consultant or Advisor||Current|
EDUCATION COUNCIL DISCLOSURES:
COI REVIEW WORKGROUP DISCLOSURES:
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: May, 2023
Expiration Date: May, 2024
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation